U.S. cannabis labelling requirements take effect under the 1906 Act

The United States Food and Drugs Act expressly named cannabis indica among ingredients whose quantity or proportion had to appear on covered product labels. President Theodore Roosevelt approved the Act on 30 June 1906, but section 13 set its commencement at 1 January 1907. This history entry uses the latter date while retaining its established identifier.

What cannabis labelling required

Section 8 defined misbranding and added specific rules for drugs and foods. A packaged drug was misbranded if its label omitted the quantity or proportion of cannabis indica, including derivatives or preparations. The food provisions also expressly listed cannabis indica. Merely naming cannabis somewhere in promotional literature was therefore not the statutory test: the package label had to disclose the relevant quantity or proportion.

The Act’s definition of a drug extended to medicines recognized in the United States Pharmacopoeia or National Formulary and substances intended to cure, mitigate or prevent disease. Its cannabis clause operated inside this wider system of product regulation.

How the rule could be enforced

Section 2 prohibited interstate and foreign movement of adulterated or misbranded food and drugs. Sections 1 and 2 also reached specified manufacture and sales in federal territories and the District of Columbia. Section 10 authorized proceedings against covered goods, while section 11 provided for examination and rejection of imports.

The FDA’s institutional history explains that the Bureau of Chemistry administered the legislation. It describes a system centred on labelling and product standards rather than advance government approval of each medicine. The law consequently supplied practical enforcement mechanisms while leaving a market for compliant medicinal products.

A control distinct from prohibition

The original database description said that the Act did not restrict the drug. That was too broad: restrictions on misbranded trade were enforceable legal controls. Equally, the express cannabis listing did not itself prohibit personal possession, cultivation or all medicinal sales, and did not establish a cannabis prescription requirement.

The FDA also cautions against reading later advertising rules into the original statute. It records that the Supreme Court in 1911 rejected the government’s interpretation that the law covered false therapeutic claims; a 1912 amendment addressed that gap, with difficulties proving fraudulent intent.

This entry replaces a Wikipedia-only account with the original statute and the regulator’s historical explanation. It makes no claim that this was the first federal measure ever to affect cannabis. It is retained as unscored context in the United States chronology because the broader historical score allocation has not been reconstructed here.^[1][2]